via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:KALY) (“KALY”) is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition to developing pharmaceutical products, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products. Earlier this year KALY announced a $100,000 wholesale order of its Hemp4mula CBD infused gum and plans to retail the gum on USMJ.com, the cannabis sector Ecommerce site from North American Cannabis Holdings, Inc. (USOTC:USMJ) (aka USMJ). Today KALY is pleased to announce it has caught up on its Hemp4mula gum production and has product in inventory now that will be listed for sale from USMJ.com next week. After making a series of announcements about its cannabis extract research and development, KALY reemphasized today its multiple go-to-market strategy to generate near term revenues from its health and wellness products in addition to developing long-term revenues from its pharmaceutical developments.
KALY has recently announced ongoing cannabis extract research and development targeting four specific health issues: Chronic Obstructive Pulmonary Disease (COPD); Type 2 Diabetes; Cancer Pain Management, and Epilepsy. The market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market for COPD treatment is anticipated to reach $14 billion by 2025. The overall pain management treatment market is anticipated to reach $83 billion by 2024. The market for epilepsy treatment is anticipated to reach $9 billion by 2022. The company has scheduled an online prestation next week for Wednesday, April 17, where management will provide details on its patented cannabis extract treatments targeting a $170 million pharmaceutical market opportunity currently under development. The company has scheduled an online prestation next week for Wednesday, April 17, where management will provide details on its patented cannabis extract treatments targeting a $170 million pharmaceutical market opportunity currently under development.
Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline which will be highlighted in the April 17 presentation.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.